Fig. 1: Novel therapy uptake.
From: Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia
Stacked areas represent the proportion of all treatment events during each month of the study period that included novel therapies (brown), did not include novel therapies (tan), or were research therapies (red). Dashed lines represent dates of FDA approval for each novel therapy. % percentage, GO gemtuzumab ozogamicin.
